The Raf/MEK/ERK kinase cascade plays a critical role in transducing growth signals from activated cell surface receptors. Using DMEK1:ER, a conditionally active form of MEK1 which responds to either b-estradiol or the estrogen receptor antagonist 4 hydroxy-tamoxifen (4HT), we previously documented the ability of this dual specificity protein kinase to abrogate the cytokine-dependency of human (TF-1) and murine (FDC-P1 and FL5.12) hematopoietic cells lines. Here we demonstrate the ability of DMEK1:ER to activate the phosphatidylinositol 3-kinase (PI3K)/Akt/p70 ribosomal S6 kinase (p70 S6K ) pathway and the importance of this pathway in MEK1-mediated prevention of apoptosis. MEK1-responsive cells can be maintained long term in the presence of b-estradiol, 4HT or IL-3. Removal of hormone led to the rapid cessation of cell proliferation and the induction of apoptosis in a manner similar to cytokine deprivation of the parental cells. Stimulation of DMEK1:ER by 4HT resulted in ERK, PI3K, Akt and p70 S6K activation. Treatment with PI3K, Akt and p70 S6K inhibitors prevented MEK-responsive growth. Furthermore, the apoptotic effects of PI3K/Akt/p70 S6K inhibitors could be enhanced by cotreatment with MEK inhibitors. Use of a PI3K inhibitor and a constitutively active form of Akt, [DAkt(Myr + )], indicated that activation of PI3K was necessary for MEK1-responsive growth and survival as activation of Akt alone was unable to compensate for the loss of PI3K activity. Cells transduced by MEK or MEK+Akt displayed different sensitivities to signal transduction inhibitors, which targeted these pathways. These results indicate a requirement for the activation of the PI3K pathway during MEK-mediated transformation of certain hematopoietic cells. These experiments provide important clues as to why the identification of mutant signaling pathways may be the Achilles heel of leukemic cell growth. Leukemia treatment targeting multiple signal transduction pathways may be more efficacious than therapy aimed at inhibiting a single pathway.
Introduction
The proliferation and suppression of apoptosis in many hematopoietic precursor cells is promoted by interleukin-3 (IL-3), granulocyte/macrophage-colony-stimulating factor (GM-CSF), stem cell factor, FL (the ligand for the tyrosine kinase receptors flt-2 and flt-3), thrombopoietin and certain other cytokines. [1] [2] [3] [4] [5] [6] Hematopoietic cell lines have been isolated which require IL-3 or in some cases GM-CSF for survival and cell proliferation. 7 The murine FDC-P1 cell line is an IL-3/GM-CSFdependent cell line isolated from the bone marrow of a DBA/2 mouse. 7 These cells represent early hematopoietic precursor cells with a colony-forming unit granulocyte/macrophage morphology. Cytokine deprivation of these cells results in rapid cessation of growth with subsequent death by apoptosis (programmed cell death). [1] [2] [3] [7] [8] [9] [10] [11] [12] In the presence of IL-3 or GM-CSF, these cells proliferate continuously; however, they are nontumorigenic when injected into immunocompromised mice. 11 Spontaneous factor-independent cells are rarely recovered from the FDC-P1 cell line making it an attractive model to analyze the effects that various genes have on signal transduction and leukemogenesis, since abrogation of cytokine dependence is an important factor in the development of leukemia. [1] [2] [3] [8] [9] [10] [11] [12] IL-3 and GM-CSF exert their biological activity by binding to the IL-3 and GM-CSF receptors, respectively (IL-3R and GM-CSFR). 1, [13] [14] [15] [16] [17] These receptors are comprised of a ligand-specific a-subunit and a common b-subunit (b c ), which is essential for signal transduction. 1, [13] [14] [15] [16] The membrane proximal domain of the b c chain is required for the induction of the Jak-STAT pathway, while the membrane distal domain is necessary for the stimulation of the Ras/Raf/MEK/ERK pathway. 15 The activation of Jak2 by IL-3 may occur by receptor aggregation resulting in the multimerization of associated Jak2 proteins.
14 Likewise, the binding of IL-3 to the receptor results in the formation of a complex, consisting of Grb2/Sos that is recruited to the b c chain by tyrosine phosphorylated Shc. [18] [19] [20] [21] [22] [23] The receptor-associated complex results in the stimulation of Ras, the phosphatidylinositol 3 kinase (PI3K)/protein kinase B (PKB/Akt) pathway (hereafter referred to as Akt) and additional signal transduction molecules such as members of the Src family of tyrosine kinases.
in the indirect or direct phosphorylation of transcription factors that regulate gene expression. PI3K can also be activated by Ras. 20 Activated PI3K can result in the subsequent activation of the downstream targets phosphatidylinositol-dependent kinase-1, Akt, p70 ribosomal S6 kinase (p70 S6K ) and NF-kB, many of which perform critical antiapoptotic functions. [20] [21] [22] [23] [24] [25] In this study, we report that aberrant activation of the Raf/MEK/ERK pathway can result in and requires the activation of the PI3K/Akt pathway.
Akt family members all contain an amino-terminal pleckstrin homology (PH) domain, a catalytic domain and finally a carboxyl-terminal domain that lacks homology with other proteins. Activation of Akt occurs in two phases: (1) targeting to the lipid-rich cell membrane by the N-terminal PH domain and (2) phosphorylation on serine/threonine residues. The PH domain may mediate binding to certain lipid activators; however, the PH domain is not necessary for Akt kinase activity. 26 Phosphorylation of T308 in the catalytic domain and S473 in the carboxyl-terminal domain results in the activation of Akt. Akt may serve to stimulate certain proteins involved in the prevention of apoptosis such as NF-kB as well as repress other proteins normally involved in the induction of apoptosis such as the forkhead transcription factors, glycogen synthetase-3 kinase, Fas, caspase 9 and cell cycle inhibitors such as p27 Kip1 . 20 Activated Akt may phosphorylate certain downstream substrates such as IkK and stimulate NF-kB activity. 20 As with other oncogenes, constitutively active forms of PI3K and Akt have been reported and certain spontaneous cytokine receptor mutants can result in constitutive activation of this pathway. [26] [27] [28] [29] Since activation of Akt by PI3K is dependent on localization of Akt to the plasma membrane, where it is subsequently phosphorylated, reported activating mutations of Akt include deletion of the N-terminal domain, which includes the PH domain. 26 In these engineered deletion mutants, the Nterminus was substituted with the v-Src-encoded myristylation site so that Akt localization to the membrane was no longer dependent on PI3K activation. These mutants must still be phosphorylated in order to be active. Additionally, two key phosphorylation sites may be mutated to aspartic or glutamic acid residues to confer constitutive activation on Akt. 26 Constitutive Akt activation has been associated with oncogenic transformation in NIH3T3 cells and the suppression of apoptosis in additional cell lines. 26, 30 Evidence suggests that the Ras/Raf/MEK/ERK pathway is intimately associated with the control of cell growth, differentiation and apoptotic machinery in myelo-monocytic cells. 15, [30] [31] [32] [33] [34] Recently, the downstream kinase ERK2 has been shown to phosphorylate the antiapoptotic Bcl-2 and the proapoptotic Bad molecules. 35, 36 Bcl-2 phosphorylation at serine 70 results in enhanced Bcl-2 antiapoptotic activity, whereas Bad phosphorylation results in its sequestering by 14-3-3 proteins. [35] [36] [37] These modifications allow Bcl-2 to bind Bax and prevent apoptosis. 20 In addition to phosphorylation by ERK, Bad may also be phosphorylated by Akt. [20] [21] [22] [23] Previous studies in FDC-P1 cells documented that a conditionally active form of MEK1, DMEK1:ER, could relieve the cytokine dependence of a subset of these cells. [38] [39] [40] In the following study, the signal transduction events required for conditionally active MEK1 to relieve the cytokine dependence of FDC-P1 cells were further examined. The ability of MEK1 to activate the PI3K/Akt pathway and the requirement of PI3K activation in supporting MEK1-responsive growth and survival in FDC-P1 cells were determined. Understanding the roles the Raf/ MEK/ERK and the PI3K/Akt pathways play in the control of cell proliferation will increase our ability to suppress leukemia.
Materials and methods

Cell lines and growth factors
Cells were maintained in a humidified 5% CO 2 incubator. The IL-3/GM-CSF-dependent murine myeloid cell line FDC-P1 7 was cultured in RPMI 1640 (RPMI, Invitrogen, Carlsbad, CA, USA) medium supplemented with 10% WEHI-3B (D À ) conditioned medium as a source of murine IL-3, and 5% iron-supplemented bovine calf serum (BCS, Hyclone, Logan, UT, USA). MEK1-dependent DMEK1:ER cells were grown in RPMI+5% FCS+1 mM b-estradiol or 500 nM 4-OH tamoxifen (4HT), an activator of the DMEK1:ER fusion protein 38 (Sigma, St Louis, MO, USA). b-estradiol and 4HT were dissolved in ethanol. DMEK1: ER-infected cells were in some cases treated with the Raf inhibitor (5-iodo-3[(3,5-dibromo-4-hydroxyphenyl)methylene]-2-indolinone, Calbiochem (San Diego, CA, USA), hereafter referred to as the Raf inhibitor), the MEK inhibitors, PD98059 (Cell Signaling, Beverly, MA, USA) or U0126 (Promega, Madison, WI, USA), the PI3K inhibitors, LY294002 and Wortmannin (Wort) (Calbiochem and Sigma), the Akt inhibitor (1L-6-hydroxymethyl-chiro-inositol2-(R)-2-O-methyl-3-O-octadecylcarbonate, hereafter referred to as the Akt inhibitor, Calbiochem), the p70 S6K inhibitor, rapamycin (Calbiochem) or the phorbol ester, phorbol 12-myristate 13-acetate (PMA, Sigma). These chemicals were dissolved in dimethyl sulfoxide (DMSO, Sigma). The optimal concentrations of the signal transduction inhibitors used were determined by titering these inhibitors on the cell lines and comparing which doses reduced [ 3 H]thymidine and induced apoptosis as determined by annexin V/PI binding with the reported IC 50 s for these drugs. The specificity and mechanism of action of these inhibitors has been described. 41 
Retroviral infection of cells
Cells were infected with a retrovirus (pBabepuro3) [38] [39] [40] encoding a fusion protein (DMEK1:ER) between a constitutively activated form of MEK1 (DN3-S218E-S222D) and the hormone-binding domain of the human estrogen-receptor. [38] [39] [40] This retrovirus also encodes resistance to the antibiotic puromycin (puro r ). In some cases, cells were also infected with a retrovirus containing a constitutively active form of Akt, DAkt(Myr + ). 42 The PH domain of Akt was deleted (DPH) and replaced with v-Src-derived myristolation site sequences (Myr + ). 42 This retrovirus contained a neomycin resistance gene neo r for selection. Puro r and neo r FDC-P1 cells were isolated by selection in 1 mg/ml puromycin or 2 mg/ml G418 in the presence of IL-3, b-estradiol or 4HT as described. 9 The nomenclature of the FDC-P1 cells is as follows: FD/DMEK1:ER for cells infected with the DMEK1:ER virus, FD/DMEK1:ER+DAkt(Myr 
Preparation of cell extracts and analysis by Western blotting
Cells were washed twice with cold phosphate-buffered saline containing 5 mM Na 2 EDTA and lysed on ice in Gold lysis buffer as described. 9 Cellular proteins were analyzed by electrophoresis through polyacrylamide gels followed by Western immunoblotting onto polyvinylidene difluoride (PVDF) membranes (Immunobilon P; Millipore, New Bedford, MA, USA). Western blots were blocked in 1% bovine serum albumin and were then incubated with the indicated primary antibody [Santa Cruz Biotechnology (SCB), Santa Cruz, CA] at a dilution of 1:1000 as described. 9 Phospho-specific ERK, Akt and p70 S6K blots were conducted as above with the exception that the secondary antibody was an a-rabbit:HRP used at 1:2000 in TBST with 5% nonfat milk. The phospho-specific ERK, Akt and p70 S6K Abs were purchased from Cell Signaling (Beverly, MA, USA). These protein samples were also run on parallel gels and probed with a nonphosphospecific Abs (Cell Signaling and SCB).
Determination of PI3K activity
Protein lysates were prepared from cells cultured in phenol-redfree RPMI containing 5% charcoal-stripped FBS for 24 h. The cells were then stimulated with IL-3 or 4HT for 5 or 30 min. In some cases, the cells were pre-incubated with 10 mM Wort (Sigma) for 1 h before the addition of IL-3 or 4HT. The method of Auger et al, 43 as modified by Zhang et al, 44 was used to measure PI3K activity in immunoprecipitates. Cells were lysed in icecold lysis buffer (150 mM NaCl, 50 mM Tris HCl pH 7.4, 1% NP40, 1% sodium deoxycholate, 1 mM sodium ortho vanadate) with proteinase inhibitors (15 mg/ml aprotinin, 0.2 mM PMSF, 10 mg/ml leupeptin). A total of 100 mg of protein was diluted to a total volume of 500 ml for each sample with lysis buffer and 2 mg of rabbit polyclonal anti-mouse PI3K p85 subunit (SCB) added followed by an overnight incubation at 41C with mixing. Protein A-agarose (Boehringer-Mannheim GmbH, Germany) was added, followed by a further 2 h incubation with mixing at 41C. Immune complexes were precipitated at 2500 Â g for 5 min at 41C and washed twice in lysis buffer, without protease inhibitors, and twice in Tris-buffered saline EDTA (TBSE) with 1 mM ortho vanadate. TBSE contains 100 mM Tris pH 7.4, 150 mM NaCl and 1 mM EDTA. The final resuspension was in 50 ml TBSE. MnCl 2 and phosphatidylinositol (Sigma) were added to final concentrations of 12.5 mM and 25 ng/ml, respectively. The reaction was started by the addition of 30 mCi of [g- 
Determination of Akt activity
Cells were deprived of 4HT for 24 h in phenol-red-free RPMI medium that contained 5% charcoal-stripped BCS. The cells were then pulsed with cytokine or 4HT for varying periods of time. Akt activity was determined using an in vitro kinase assay. An aAkt1 Ab (SCB) and protein A-sepharose beads (Amersham) were used to immunoprecipitate the Akt1 protein overnight from 100 mg of total protein lysate. The immunoprecipitates were washed once in GLB, once in GLB+500 mM NaCl once in Akt wash buffer (25 mM HEPES, pH 7.5 500 mM NaCl, 10% glycerol, 0.2 mM EGTA and 1% Triton X-100) and once in Akt reaction buffer (20 mM HEPES, pH 7.5, and 10 mM MgCl 2 ). The immunoprecipitate was then used in a kinase reaction containing 20 mM HEPES pH 7.5, 10 mM MgCl 2 , 10 mM MnCl 2 , 1 mM DTT, 200 mM ATP, 1 mM [g-32 P]ATP and 1 mg histone 2B (H2B, Roche Diagnostics, Indianapolis, IN, USA) as a substrate. The reactions were carried out at 301C for 30 min before being stopped with 7.5 ml of sample buffer and boiling for 3 min. The reaction mixtures were electrophoresed through a 14% polyacrylamide gel, transferred to PVDF and exposed to a X-ray film. Western blots were preformed with 25 mg of the same samples with the aAkt1 Ab.
Determination of ERK activity
Cells were deprived of 4HT for 24 h in phenol-red-free RPMI medium that contained 5% charcoal-stripped FCS. Then the cells were pulsed with cytokine or 4HT, for 15 min. ERK2 activity was determined after immunoprecipitation with an aERK2 antibody (SCB). The immunoprecipitated proteins were then used in a radioactive ERK assay as described.
9,38-40
Caspase 3 activation and annexin V apoptosis assays Caspase 3 activity was measured using the APO LOGIXt carboxyfluorescein caspase detection kit (Cell Technology, Minneapolis, MN, USA). Approximately 1 Â 10 7 exponentially growing cytokine-dependent, MEK1-responsive or MEK1/Aktresponsive cells were collected by centrifugation and annexin V/PI assays were performed as described. 30, 45 Controls, which were unstained, stained with annexin V only, or stained with PI only, were used to calibrate the FACS analyzer for each experiment.
Results
Effects of DMEK1:ER on cytokine dependence and downstream ERK activity
We recently determined the effects of a conditionally active form of MEK1 on the cytokine dependence of hematopoietic cells. [38] [39] [40] FDC-P1 cells were infected with a retrovirus encoding DMEK1:ER or an empty vector encoding only puromycin resistance (puro r ). While infection with the DMEK1: ER encoding retrovirus allowed some FDC-P1 cells to grow in medium lacking exogenous IL-3, no empty retroviral vectorinfected cells were recovered in medium containing puromycin and either b-estradiol or 4HT. [38] [39] [40] The conditional activity of the DMEK1:ER protein was determined in FD/DMEK1:ER cells by treatment of 4HT-deprived cells with 4HT, IL-3, PMA or ethanol, and examining the presence of activated forms of downstream ERK by Western blotting (Figure 1a) . 4HT was used in these studies as it is a more specific activator of DMEK1:ER than b-estradiol. Treatment of the cells with 4HT, IL-3 and PMA led to the detection of activated forms ERK (Figure 1a) . Furthermore, treatment of the cells with 4HT, IL-3 and PMA led to the detection of ERK activity as determined by a kinase assay (Figure 1b and data not presented) . Thus, these cells contain a conditional MEK1 gene, which can be activated by 
Effects of inhibitors on DNA synthesis
In order to determine the involvement of the PI3K/Akt/p70 S6K pathway on MEK1-mediated proliferation, DNA synthesis was examined in the MEK-responsive cells treated with pharmacological inhibitors, which target the Raf/MEK/ERK and PI3K/Akt/ p70 S6K pathways (Figure 2 ). In this figure, the data were plotted to maximize the visualization of the differences in the data, that is why the individual panels do not have the same scales on the Y-axis. The Raf inhibitor suppressed cytokine more than MEK1-mediated DNA synthesis (panel A). The effects of this Raf inhibitor were examined as it has been speculated that MEK may induce Raf activity under certain circumstances. 1 Since this inhibitor did not suppress MEK1-mediated DNA synthesis, it was not used in further studies. The MEK inhibitors (PD98059 and U0126) suppressed cytokine-and MEK-mediated DNA synthesis (panels B and C). MEK1-mediated DNA synthesis was more sensitive to the MEK inhibitors than cytokine-mediated DNA synthesis. Doses of 25 mM PD98059 and 10 mM U0126 were used in further studies based upon these and similar titration experiments using the induction of apoptosis as a readout (see Figure 6 and Table 1 ). The PI3K, Akt and p70 S6K inhibitors suppressed MEK1, as well as, cytokine-mediated DNA synthesis (panels D, E and F). Doses of 10 mM LY294002, 25 mM Akt and 5 nM rapamycin were used in subsequent studies. In summary, data from [ 3 H]thymidine incorporation assays indicated a strong requirement for functional PI3K, Akt and p70 S6K activities for MEK1-mediated DNA synthesis.
Activation of MEK1 stimulates PI3K, Akt and p70
S6K activities
The effects of MEK1 activation on the PI3K pathway were examined (Figures 3-5) . Treatment of MEK1-responsive cells with IL-3 and 4HT resulted in the detection of PI3K activity (Figure 3 ). IL-3 induced approximately four-fold higher levels of PI3K activity than untreated cells after 5 min (panel A). The level of PI3K activity decreased after 30 min of IL-3 treatment (panel B). Higher levels of PI3K activity were detected after 30 min (panel B) than 5 min (panel A) of 4HT treatment. The specificity of the induction of the PI3K activity was examined by the treatment of the cells with the PI3K inhibitor Wort. Wort was used in these experiments, as it is a more conventional and specific inhibitor of PI3K than LY294002. 41 In these PI3K assays, the cells were only treated for 1 h, which avoids the problems associated with the lability of Wort. 41 Wort pretreatment for 1 h suppressed the induction of PI3K treatment after IL-3 and 4HT addition (panels A and B). The effects of Wort on IL-3-and MEK1-mediated DNA synthesis were also examined. Wort suppressed both 4HT-and IL-3-mediated DNA synthesis (panel C). Thus, inhibition of PI3K activity by two different PI3K inhibitors, which act by different mechanisms, suppressed MEK1-responsive DNA synthesis.
Activation of Akt was examined by two different techniques, which yielded similar results. Western blotting was performed with Akt activation-specific Abs (T308 and S473) (Figure 4 , panel A). Akt kinase assay were performed with immunoprecipitated Akt protein and H2B as a substrate (Figure 4, panel B) . After 5 min of 4HT treatment, induction of Akt activity was detected by both Western blotting and kinase assays. A similar time period of ERK activation was observed after 4HT treatment of these cells (Figure 1, panel A) . As a control, the presence of activated forms of Akt was also examined after PMA treatment. PMA resulted in the prolonged detection of activated forms of Akt (Figure 4, panel A) , as well as ERK (Figure 2, panel A) . Effects of DMEK1:ER on ERK activity. MEK1-responsive FD/DMEK1:ER cells were deprived of 4HT for 24 h before being stimulated with IL-3, PMA, 4HT or ethanol for the indicated time periods. Western blot and ERK activities were determined with phospho-specific ERK Ab and an ERK assay as described in Materials and methods. The kinase assay was performed on protein lysates recovered from cells stimulated with IL-3 or 4HT for 15 min. As loading controls, Western and kinase blots were probed with an aERK2 Ab.
Interactions between MEK and PI3K/Akt/p70 S6K in growth and apoptosis WL Blalock et al Akt activity was detected within 5 min of IL-3 stimulation of MEK1-responsive cells. Akt activity dropped to lower levels approximately 1-2 h after IL-3 addition, but was detected at elevated levels 4-12 h after addition (Figure 4, panel B) . MEK1 activation by the addition of 4HT resulted in the rapid activation of Akt (5-60 min) in MEK1-responsive FD/DMEK1:ER cells (Figure 4, panel B) . Akt activity then dropped to near basal levels around 2 h and did not rise again until approximately 4 h of treatment. Thus, Akt activity displayed a biphasic response to both IL-3 and 4HT, as increases in Akt activity were detected early which were followed by decreases in activity, then finally elevated levels of Akt activity were detected after 4 h of treatment. p70 S6K phosphorylation was examined in MEK1-responsive FD/DMEK1:ER cells using a phospho-specific antibody. p70 
PI3K is required for MEK1-mediated growth
In order to determine if the requirement of PI3K activity in MEK1-responsive proliferation could be by-passed by Akt, the induction of apoptosis was determined in MEK1 and MEK1/Aktresponsive cells. MEK1/Akt-responsive [FD/DMEK1:ER+DAkt(-Myr + )] cells were derived by infecting cytokine-dependent FD/ DMEK1:ER cells, with a DAkt(Myr + ) containing retrovirus and isolation of cells, which proliferated in the presence of 4HT and G418. Infection with an activated form of Akt increased the recovery of MEK1-responsive cells approximately 100-fold. Infection with activated Akt by itself was insufficient to abrogate the cytokine dependence of FDC-P1 cells, indicating the importance of the Raf/MEK/ERK pathway in controlling cytokine dependence. The effects of either MEK1 alone or MEK1+Akt on the induction of apoptosis were determined in the presence of inhibitors which targeted the PI3K/Akt/p70S6K or Raf/MEK/ERK pathways ( Figure 6 and Table 1 ). Two independent assays for apoptosis were used in the following studies, detection of caspase 3 activation and annexin V/PI binding. Both of these techniques can be used to examine the induction of apoptosis. [46] [47] [48] [49] [50] An example of these techniques is presented in Figure 6 . The effects of PI3K pathway inhibitors on the induction of apoptosis on these and other MEK1-and Akt-infected cells were determined (Table 1) . In these experiments, the effects of signal transduction inhibitors on three different types of DMEK1:ERinfected cells were examined, cytokine-dependent FD/DME-K1:ER(IL3) The effects of MEK inhibition on apoptosis were examined. When the cells were cultured in the presence of IL-3 and the MEK inhibitor, the percentage of caspase 3-positive cells ranged from 10 to 15% and the percentage of cells that registered as annexin V positive ranged from 18 to 30%. In contrast, when the cells were cultured in the presence of 4HT and the MEK inhibitor, the percentage of caspase 3-positive cell ranged from 43 to 80% and the percentage of annexin-positive cells ranged from 58 to 90%. The cells which grew in response to activated MEK1 alone, were more sensitive to the effects of the MEK inhibitor (80 and 90% caspase 3 and annexin positive, respectively) than the MEK/Akt-responsive cells, which activated Akt (43 and 58% caspase 3 and annexin positive, respectively), Effects of MEK1 on PI3K activity. PI3K activity was examined in FD/DMEK1:ER cells that had been deprived of 4HT for 24 h and then subsequently stimulated with 4HT or IL-3 for 5 and 30 min (panels A and B, respectively). In some cases, the cells were pretreated with 10 mM Wortmannin (Wort) for 1 h before 4HT or IL-3 treatment. PI3K activity was determined by the incorporation of 
Discussion
Previously, we examined the ability of the dual-specific kinase MEK1 to transform a variety of hematopoietic cells to cytokine independence. Our studies revealed that aberrant MEK1 activity resulted in the conversion of a small subset of cells to cytokine independence. [38] [39] [40] The transformation efficiency of MEK1 could be enhanced by the forced overexpression of the antiapoptotic protein Bcl-2, and we have since observed that elevated PI3K/Akt activity could also enhance the frequency of isolation of MEK1-responsive cells. In this study, we have examined some of the early effects of MEK1 activation in hematopoietic cells. Our results suggest that MEK1 may activate the PI3K/Akt/p70S6K pathway by MEK1 either directly or indirectly phosphorylating PI3K. Although beyond the scope of this paper, which focuses on the effects of these pathways on apoptosis and drug sensitivity, experiments are in progress to determine how MEK1 activates the PI3K pathway. Biphasic increases in Akt activity were observed in response to IL-3 and MEK activation. The initial activation of ERK, PI3K, Akt and p70 S6K occurred within 5 min of 4HT treatment. This rapid activation was not observed after ethanol treatment and was not likely because of the de novo expression of autocrine growth factors. The second increase in Akt activity may result from the autocrine synthesis of growth factors, which serve to 'restimulate' the pathway. We have previously observed a biphasic induction of ERK activity in response to MEK1 activation in these cells. [38] [39] [40] Of particular interest was the observation that inhibition of PI3K resulted in decreased long-term survival. PI3K is responsible for the phosphorylation of phosphatidylinositol converting it into a phosphatidylinositol 3 0 -phosphate second messenger DMEK1:ER induces p70 S6K phosphorylation. MEK1-responsive FD/DMEK1:ER cells were starved for 24 h and then treated with 4HT for the indicated times. Cells were lysed and the lysates electrophoresed on 10% SDS-PAGE gels. The gel was transferred to PVDF and immunoblotted with phospho-specific p70 S6K Ab (1:1000) and an a-rabbit:HRP conjugate Ab. A parallel gel was Western blotted and probed with an Ab that recognizes total p70 S6K (nonphosphospecific Ab).
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Figure 6
Effects of signal transduction inhibitors on the induction of apoptosis. Cells were treated for 48 h with 4HT in medium containing DMSO (0.25%) (panels A and B) or PI3K inhibitor (LY294002, 10 mM) (panels C and D). 31  20  19  34  18  13  4HT  F  F  F  27  35  18  14  IL-3  PI3K  47  46  17  35  19  34  4HT  PI3K  F  F  83  90  41  50  IL-3  Akt  20  18  25  48  22  27  4HT  Akt  F  F  79  88  19  33  IL-3  p70S6K  19  20  10  32  15  29  4HT  p70S6K  F  F  87  94  34  48  IL-3  MEK  10  19  10  18  15  30  4HT  MEK  F  F  80  90  43  58  IL-3  PI3K+MEK  85  86  34  46  60  74  4HT  PI3K+MEK  F  F  95  98  90  92  IL-3  Akt+MEK  59  59  20  32  41  62  4HT  Akt+MEK  F  F  95  97  76  85  IL-3  p70S6K+MEK  34  36  17  29  61  72  4HT  p70S6K+MEK  F  F  94  91  78  94   a The percentage of caspase 3-positive cells was determined as presented in Figure 6 , The percentage of annexin V-positive cells represent the top left (annexin V positive, PI negative) and top right (annexin V positive, PI positive) quadrants of cells were determined as presented in Figure 6 . F=Not done, Cytokine-dependent FD/DMEK1:ER cells were not cultured in the absence of IL-3 as greater than 75% of the cells would register as apoptotic in these conditions.
Interactions between MEK and PI3K/Akt/p70 S6K in growth and apoptosis WL Blalock et al molecule responsible for the recruitment of various signaling molecules to the membrane where they are subsequently activated. One of these recruited molecules is Akt, which has been shown to phosphorylate Bad resulting in its sequestering by 14-3-3 protein family members, thus freeing Bcl-2 and resulting in enhanced cell survival. Another downstream consequence of the activation of PI3K is the activation of the p70 S6K , which phosphorylates the S6 ribosomal protein as well as additional targets including Bad. 51 In order to determine if Akt activation was the main role that PI3K was playing in MEK1-mediated transformation, FD/DMEK1:ER cells were infected with a constitutive DAkt(- Myr  + ) . Surprisingly, the combination of MEK1 and Akt was unable to suppress the requirement for PI3K, as double infectants were unable to survive in the presence of 4HT and the PI3K inhibitor. These data indicated that activation or recruitment of additional signal transduction molecules activated by PI3K, in addition to Akt, are required for MEK1-responsive growth and survival.
In general, FDC-P1 hematopoietic cells, which grew in response to MEK and Akt, displayed increased resistance to MEK and PI3K/Akt/p70 S6K inhibitors when compared to cells, which just grew in response to activated MEK. However, when the MEK1/Akt-responsive cells were cultured in IL-3, they were more sensitive to cotreatment with MEK and PI3K/Akt/p70 S6K pathway inhibitors. This may have therapeutic implications as these cells have revealed their Achilles heel, in that they are very sensitive to MEK and PI3K pathway inhibition.
These cells should be useful in dissecting the interactions between signaling molecules, which result in the prevention of apoptosis. Moreover, these cells lines may prove useful in identifying which signal transduction pathways are better suited for targeted therapy. These studies also indicate that treatment of transformed hematopoietic cells with combinations of inhibitors may be a more effective method to inhibit leukemic growth than monotherapy. These experiments illustrate the importance of identifying the precise genetic lesions in leukemia, which may enable the physician to precisely treat the cancer patient with the correct cocktail of inhibitors. Recently, an important series of papers has been published in Leukemia which document the efficacy of treatment of leukemic cells with inhibitors, which target specific signal transduction pathways. [53] [54] [55] [56] [57] [58] [59] [60] [61] Targeted cancer therapy provides promise to reduce the devastating toxic side effects of nonspecific chemotherapy.
